SCI
TVTX icon

S&CO Inc’s Travere Therapeutics TVTX Stock Holding History

S&CO Inc’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Hold
56,000
– – 0.1% 120
2025
Q4 		$2.14M Hold
56,000
– – 0.13% 114
2025
Q3 		$1.34M Buy
56,000
+28,000
+100% +$526K 0.08% 132
2025
Q2 		$414K Buy
+28,000
New +$464K 0.03% 178

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

S&CO Inc's TVTX Position: Q1 2026 in Review

S&CO Inc held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 56,000 shares worth $1.66M. The position accounts for 0.1% of the portfolio, ranked #120.

S&CO Inc first reported a position in TVTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.14M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • S&CO Inc held 56,000 shares of Travere Therapeutics worth $1.66M as of Q1 2026.
  • S&CO Inc left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up 0.1% of S&CO Inc's portfolio in Q1 2026, its #120 holding.
  • S&CO Inc first reported a position in Travere Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • S&CO Inc's Travere Therapeutics position peaked at $2.14M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on S&CO Inc's 13F filing for Q1 2026, filed 7 May 2026.